Santhera Pharmaceuticals Holding AG

LSE:0QN1 Stock Report

Market Cap: CHF 208.1m

Santhera Pharmaceuticals Holding Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of 0QN1?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders55,8170.443%
Private Companies280,1372.22%
Institutions716,4545.69%
Public Companies2,715,81621.6%
General Public8,827,21470.1%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 36.7%.

Top Shareholders

Top 18 shareholders own 29.92% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
11.2%
Catalyst Pharmaceuticals, Inc.
1,414,688CHF 23.4m0%no data
10.3%
Idorsia Ltd
1,301,128CHF 21.5m0%no data
4.17%
JPMorgan Chase & Co, Brokerage and Securities Investments
524,785CHF 8.7m-49.1%no data
2.22%
Santhera Pharmaceuticals (Schweiz) AG
280,137CHF 4.6m-86%no data
0.53%
ZKB Asset Management
66,625CHF 1.1m2.22%no data
0.38%
Zürcher Kantonalbank, Investment Arm
47,239CHF 780.4k0%0.01%
0.25%
Thomas Meier
31,083CHF 513.5k0%no data
0.2%
Pictet Asset Management Limited
25,042CHF 413.7k0%no data
0.18%
Dimensional Fund Advisors LP
23,197CHF 383.2k153%no data
0.17%
BlackRock, Inc.
21,620CHF 357.2k6.55%no data
0.11%
Philipp Gutzwiller
13,497CHF 223.0k0%no data
0.061%
Lombard Odier Asset Management (Switzerland) SA
7,695CHF 127.1k0%no data
0.036%
Dario Eklund
4,500CHF 74.3k0%no data
0.025%
Bradley Meyer
3,091CHF 51.1k0%no data
0.021%
Shabir Hasham
2,646CHF 43.7k0%no data
0.0079%
Günther Metz
1,000CHF 16.5k0%no data
0.001%
Deka Investment GmbH
130CHF 2.1k0%no data
0.00096%
State Street Global Advisors, Inc.
121CHF 2.0k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/10 15:28
End of Day Share Price 2025/02/07 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Santhera Pharmaceuticals Holding AG is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Maurizio BernasconiBank am Bellevue
Silvia SchanzBank Vontobel AG
Barbora BlahaCredit Suisse